Kesler Norman & Wride’s AbbVie ABBV Stock Holding History

Kesler Norman & Wride’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.33M	Sell	5,291 -150	-3%	-$32.3K	0.21%	116
2026 Q1	$1.18M	Buy	5,441 +41	+0.8%	+$9.1K	0.2%	111
2025 Q4	$1.23M	Buy	5,400 +1,205	+29%	+$275K	0.21%	108
2025 Q3	$746K	Sell	4,195 -1,044	-20%	-$213K	0.15%	141
2025 Q2	$974K	Buy	5,239 +73	+1%	+$13.6K	0.17%	126
2025 Q1	$1.08M	Buy	5,166 +971	+23%	+$189K	0.21%	103
2024 Q4	$746K	Buy	+4,195	New	+$771K	0.16%	136

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Kesler Norman & Wride's ABBV Position: Q2 2026 in Review

Kesler Norman & Wride reduced its AbbVie (ABBV) stake by 2.8% in Q2 2026, selling an estimated $32.3K and leaving 5,291 shares worth $1.33M. The position accounts for 0.21% of the portfolio, ranked #116.

Kesler Norman & Wride first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Kesler Norman & Wride held 5,291 shares of AbbVie worth $1.33M as of Q2 2026.
Kesler Norman & Wride sold 150 AbbVie shares in Q2 2026, an estimated $32.3K.
AbbVie made up 0.21% of Kesler Norman & Wride's portfolio in Q2 2026, its #116 holding.
Kesler Norman & Wride first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Kesler Norman & Wride's 13F filing for Q2 2026, filed 23 Jul 2026.